Stock Market Reviews

ABVX (ABIVAX Société Anonyme) News

Get the latest news, insights, and market updates on ABVX (ABIVAX Société Anonyme). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Europe’s Biotech Standout Faces Crucial Year After 1,300% Rally
  After a meteoric rally, it’s now worth more than $8 billion — and some analysts see the potential for even more gains. The optimism began in July when Abivax announced positive data for its experimental medicine to treat a chronic inflammatory bowel disease. Investors are eyeing whether patients with ulcerative colitis taking Abivax’s pill — called obefazimod — will stay in remission.
  Dec 4, 2025 - $ABVX
• Assessing Valuation: ABIVAX (ENXTPA:ABVX) Shares Surge 57% Over 90 Days
  ABIVAX Société Anonyme (ENXTPA:ABVX) has been on investors’ radar after its stock posted a strong gain over the past month, delivering a 16% return. The company has also shown impressive annual revenue growth, which signals underlying momentum. See our latest analysis for ABIVAX Société Anonyme. ABIVAX Société Anonyme’s share price has surged 57% over the past 90 days, and its year-to-date share price return stands at an astounding 1,193.96%. This momentum suggests investors are waking up to...
  Nov 16, 2025 - $ABVX
• Medicxi Announces €500 Million Fund V
  Medicxi, a leading European life sciences venture capital firm, today announced the closing of Medicxi V, a €500 million fund dedicated to building and backing innovative biotechnology companies with clear product visions to transform patient care. The oversubscribed fund closed with strong support from existing limited partners and a select group of new institutional investors. The Fund will focus on Medicxi's pioneering asset-centric investment model.
  Nov 14, 2025 - $ABVX
• Abivax SA Sponsored ADR (ABVX) Upgraded to Buy: Here's What You Should Know
  Abivax SA Sponsored ADR (ABVX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
  Nov 13, 2025 - $ABVX
• Are Medical Stocks Lagging Abivax SA Sponsored ADR (ABVX) This Year?
  Here is how Abivax SA Sponsored ADR (ABVX) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.
  Nov 13, 2025 - $ABVX
• Caterpillar upgraded, Elf Beauty downgraded: Wall Street's top analyst calls
  Caterpillar upgraded, Elf Beauty downgraded: Wall Street's top analyst calls
  Nov 6, 2025 - $ABVX
• Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis
  Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis Improvements across all patient reported outcomes (PROs) were observed from baseline to Week 8 in all PRO instruments utilized in the ABTECT induction trials evaluating bowel urgency, sleep interruption, fatigue, quality of life, and work productivity for both 50mg and 25m
  Nov 3, 2025 - $ABVX
• Barclays Initiates ABIVAX Société (ABVX) With Overweight Rating
  ​ABIVAX Société Anonyme (NASDAQ:ABVX) is one of the Hot Growth Stocks to Invest in Now. On October 13, Etzer Darout from Barclays initiated ABIVAX Société Anonyme (NASDAQ:ABVX) with an Overweight rating and a $142 price target. ​Analysts noted that they initiated coverage on eight companies in the inflammation, immunology, oncology, and rare disease sectors. He […]
  Oct 19, 2025 - $ABVX
• A Look at Abivax (ENXTPA:ABVX) Valuation Following Phase 3 Success for Obefazimod in Ulcerative Colitis
  ABIVAX Société Anonyme (ENXTPA:ABVX) just released new late-breaking Phase 3 trial data for obefazimod, showing positive clinical responses and remission rates in patients with moderate to severely active ulcerative colitis. The study also reaffirmed a favorable safety profile. See our latest analysis for ABIVAX Société Anonyme. After the late-breaking Phase 3 results for obefazimod, ABIVAX Société Anonyme’s momentum has shifted dramatically. The stock’s 1-day share price return of 3.54%...
  Oct 9, 2025 - $ABVX
• Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday Amid AMD-OpenAI AI Chip Deal, Rate Cut Hopes
  The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.3% and the actively trad
  Oct 6, 2025 - $ABVX